 Latest NewsOctober 2008 Photopharmica is currently conducting a proof of principle clinical trial to evaluate the use of photodynamic therapy using PPA 904 for the eradication of Staphylococcus aureus (SA) and its antibiotic resistant form MRSA. Around 30% of the population are carriers of SA/MRSA and the main reservoir is in the nose. Whilst carriers are normally perfectly healthy and do not develop infection, they can be a source of infection for vulnerable individuals in hospital or even for themselves if they require surgery. The current treatment for eradication takes at least 3 – 4 days and 10 – 15 treatments. Photopharmica’s trial is designed to see if PDT can achieve complete eradication in 1 – 2 treatments. Each treatment needs only the addition of a gel into the lower part of the nose, followed by shining a beam of light to activate the gel. The trial is ongoing but already there is evidence that PDT can reduce the levels of SA/MRSA in the nose by more than 90% in a single treatment. October 2008 Photopharmica is pleased to announce that it has received two Notices of Grant on US patent applications that cover the company’s key business areas. One application covers wound healing applications of the Company’s compounds and the other application covers novel compounds that broaden the portfolio of compounds available for commercialisation. August 2008 Photopharmica is pleased to announce that it has received a Notice of Allowance indication for a Canadian patent application. This application will proceed to Grant shortly. The application covers novel compounds that broaden the portfolio of compounds available for commercialisation. August 2008 Photopharmica is pleased to announce the grant of one of its patent families in Mexico. This patent covers anti-infective use of the Company’s compounds. July 2008 Photopharmica is pleased to announce that it has received two Notice of Allowance indications for USA patent applications that cover the Company’s key business areas. These applications will proceed to Grant shortly. One such application covers wound healing uses of the Company’s compounds and the other application covers novel compounds that broaden the portfolio of compounds available for commercialisation. July 2008 Photopharmica is pleased to announce the grant of two of its patent families in the USA and Europe. These patents cover anti-infective uses of the Company’s compounds and novel compounds for use in PDT, that broaden the portfolio of compounds available for commercialisation.  |
